Central to our mission to address the everyday challenges associated with existing therapies for rare and chronic diseases, Chiasma is developing octreotide capsules (conditionally trade named Mycapssa®) for the potential maintenance treatment of adults with acromegaly.
Octreotide capsules employ our proprietary Transient Permeability Enhancer (TPE®) technology to deliver an oral form of octreotide for the management of acromegaly.
Pipeline Expansion Leveraging TPE® Technology
Chiasma plans to announce its pipeline expansion plans to develop one or more new oral therapies that target rare and serious chronic diseases with unmet needs, following the anticipated approval of Mycapssa® for the maintenance treatment of adults with acromegaly.
We are currently evaluating oral octreotide capsules, conditionally trade named “MYCAPSSA”, for the maintenance treatment of adults with acromegaly.
Our clinical trials are designed to assess the safety and effectiveness of our therapies.